Connect with us

Biotech

Better Opens a Subsidiary in Spain and Projects 5 Million Revenues Before 2025

Better works with healthcare professionals to determine which type of medications are best for patients, after having analyzed and parameterized their data. The company’s platform, Better Meds, provides an electronic prescription and medication administration solution, which allows hospitals and health professionals to have a greater therapeutic and clinical vision of their patients’ situation.

Published

on

Better, the Slovenian company, which collects and monitors patient data for healthcare organizations, will open a subsidiary in Barcelona, ​​through which it expects to earn €5 million next year, according to Tomaž Gornik, the group’s CEO.

The biotech company will invest half a million euros this year in the subsidiary and next year another million euros, which will go to the marketing department and the logistics construction of the subsidiary.

Better already had subsidiaries in Germany, the United Kingdom, and Ireland, and now it has entered the Spanish market because, “in addition to being one of the largest European markets, it is a good platform for entry into America”, according to Gornik, who also points out that in the national market, there are “many international companies in the sector through which beneficial agreements can be reached.”

If you want to find more details about Better and read the latest business news of the day, download for free our companion app Born2Invest.

Better has reached an agreement with sixty Catalan hospitals

Better’s first project in Spain has been an agreement with CatSalud, the Catalan health service, to implement one of the company’s platforms, Better Meds. The platform allows the interconnection of health data in more than sixty Catalan hospitals.

Better works with healthcare professionals to determine which type of medications are best for patients, after having analyzed and parameterized their data. The company’s platform, Better Meds, provides an electronic prescription and medication administration solution, which allows hospitals and health professionals to have a greater therapeutic and clinical vision of their patients’ situation.

“Better Meds minimizes the risk of medication-related safety issues, avoids the introduction of redundant information, and allows professionals easy access to data,” the company said.

The company will seek to continue growing in Spain, especially in the south of the country

After the agreement, Better seeks to continue growing in Spain and aspires to new projects in the south of the country, specifically in Malaga or Seville, although they regret that “it is difficult to foresee where the next steps will be taken due to the high bureaucracy in the public sector.”

In addition, the group identifies Galicia, the Basque Country, and Andalusia as potential markets, since “their logistics and health data transfer systems have become very outdated,” said Gornik, who added that since the start of the Covid-19 pandemic, “Many healthcare systems have discovered that they have no real control over their data.”

__

(Featured image by  jarmoluk via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.